Vanda Pharmaceuticals (Vanda Pharmaceuticals) Change In Receivables : $-12.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Change In Receivables?

Vanda Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $-2.6 Mil. It means Vanda Pharmaceuticals's Accounts Receivable increased by $2.6 Mil from Dec. 2023 to Mar. 2024 .

Vanda Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.7 Mil. It means Vanda Pharmaceuticals's Accounts Receivable increased by $0.7 Mil from Dec. 2022 to Dec. 2023 .

Vanda Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $36.7 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vanda Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 70.58.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vanda Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $313.7 Mil.

Vanda Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Vanda Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Change In Receivables Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

2.34

-3.77

-2.47

-1.09

-0.71

Vanda Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															8.90	-9.10	4.33	-4.84	-2.59

Vanda Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.2 Mil.

Vanda Pharmaceuticals (NAS:VNDA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vanda Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	36.713	/	47.462	*	91
=	70.58

2. In Ben Graham's calculation of liquidation value, Vanda Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Vanda Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	394.142	-	108.687	+	0.75 * 36.713	+	0.5 * 1.505
=	313.7

Vanda Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VM4:Germany VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Executives

Joakim Wijkstrom	officer: SVP, Chief Marketing Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran	officer: VP, Acting CFO & Treasurer	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams	officer: SVP & General Counsel	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos	director, officer: Chief Executive Officer	9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks	officer: SVP, Business Development	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins	director	1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones	officer: Chief Corp. Affairs Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos	director	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan	director	20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly	officer: SVP, CFO, Treasurer & Secretar	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi	officer: SVP, General Manager Europe	2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341